NCT01990157View on ClinicalTrials.gov

Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

February 28, 2017

Conditions

Rheumatoid Arthritis

Interventions

DRUG

TAB08

Weekly intravenous administration in escalating doses.

Trial Locations (2)

115522

State Scientific and Research Rheumatology Institute, Moscow

150003

Clinical Emergency Hospital of Yaroslavl, Yaroslavl

All Listed Sponsors

lead

Theramab LLC

INDUSTRY

NCT01990157 - Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter